Lifecore Biomedical (LFCR) revenue breakdown
By segment, Lifecore is the largest at 59% of fiscal 2022 revenue, growing 14% a year over 6 years.
By product, CDMO is the largest at 70% of fiscal 2025 revenue; HA manufacturing grew fastest, 14% a year over 4 years.
Revenue by segment
Fiscal years, as Lifecore Biomedical reports them in its 10-K filings; fiscal 2022 total $186M.
| Segments | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | Share |
|---|---|---|---|---|---|---|---|---|
| Lifecore | $50M | $59M | $65M | $76M | $86M | $98M | $109M | 59% |
| Curation Foods | — | $410M | $459M | $482M | $74M | $73M | $76M | 41% |
| Packaged Fresh Vegetables | $424M | — | — | — | — | — | — | — |
| Other Segments | $3M | — | — | — | — | — | — | — |
Revenue by product
Fiscal years, as Lifecore Biomedical reports them in its 10-K filings; fiscal 2025 total $129M.
| Products | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|
| CDMO | $76M | $86M | $76M | $97M | $90M | 70% |
| HA manufacturing | $23M | $23M | $27M | $32M | $39M | 30% |
| Technology | $2M | — | — | — | — | — |
| Other | — | $2M | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for LFCR.
Open LFCR in InvestinglyQuestions
Where does Lifecore Biomedical make its money?
In fiscal 2022, by segment: Lifecore $109M, Curation Foods $76M.
From Lifecore Biomedical's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.